A Phase 3, Open-label Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a gating or Residual Function Mutation (F/G and F/RF Genotypes)